Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Karthik Ramasamy, Kara-Louise Royle, Robert Cicero, Ruth de Tute, Matthew Jenner, Ceri Bygrave, Rakesh Popat, Dipal Mehta, Laura Chiecchio, Berrin Balik, Mohammad Kazeroun, Guy Pratt, Catherine Olivier, Lorna Barnard, Sharon Jackson, Charlotte Kennaway, Gordon Cook, Alan Chant, David Meads, Bryony Dawkins, Michael Chapman, Graham Jackson, Andrew Chantry, Martin Kaiser, Jonathan Sive, Sarah Gooding, Eileen Boyle, Christopher Parrish, Dean Smith, Y L Tracey Chan, Roger Owen, David Cairns, Kwee Yong
Institutions: University of Oxford, University of Leeds, Leeds Teaching Hospitals NHS Trust, University Hospital Southampton NHS Foundation Trust, University Hospital of Wales, University College Hospital, St Bartholomew's Hospital, University of Birmingham, University of Cambridge, Newcastle University, University of Sheffield, Institute of Cancer Research, MRC Weatherall Institute of Molecular Medicine, University College London, Nottingham City Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417001834
Cites:
Cited by:
Related to: